- Home
- IXHL vs NRXP Comparison
IXHL vs NRXP Comparison
Compare IXHL & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IXHL
- NRXP
- Stock Information
- Founded
- IXHL 2001
- NRXP 2015
- Country
- IXHL Australia
- NRXP United States
- Employees
- IXHL N/A
- NRXP N/A
- Industry
- IXHL
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- IXHL
- NRXP Health Care
- Exchange
- IXHL Nasdaq
- NRXP Nasdaq
- Market Cap
- IXHL 49.1M
- NRXP 58.5M
- IPO Year
- IXHL N/A
- NRXP N/A
- Fundamental
- Price
- IXHL $0.35
- NRXP $3.14
- Analyst Decision
- IXHL
- NRXP Strong Buy
- Analyst Count
- IXHL 0
- NRXP 5
- Target Price
- IXHL N/A
- NRXP $31.40
- AVG Volume (30 Days)
- IXHL 30.9M
- NRXP 434.7K
- Earning Date
- IXHL 11-13-2025
- NRXP 11-13-2025
- Dividend Yield
- IXHL N/A
- NRXP N/A
- EPS Growth
- IXHL N/A
- NRXP N/A
- EPS
- IXHL N/A
- NRXP N/A
- Revenue
- IXHL $86,000.00
- NRXP N/A
- Revenue This Year
- IXHL $1,188.37
- NRXP N/A
- Revenue Next Year
- IXHL N/A
- NRXP $395.09
- P/E Ratio
- IXHL N/A
- NRXP N/A
- Revenue Growth
- IXHL 616.67
- NRXP N/A
- 52 Week Low
- IXHL $0.08
- NRXP $1.12
- 52 Week High
- IXHL $3.12
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- IXHL 38.13
- NRXP 50.20
- Support Level
- IXHL $0.33
- NRXP $3.05
- Resistance Level
- IXHL $0.43
- NRXP $3.29
- Average True Range (ATR)
- IXHL 0.03
- NRXP 0.25
- MACD
- IXHL -0.00
- NRXP -0.03
- Stochastic Oscillator
- IXHL 14.08
- NRXP 22.47
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.